P regnancy is associated with increased risk of thrombosis among women with mechanical prosthetic heart valves. 1 The largest literature review of women with a prosthetic heart valve who were on anticoagulation during pregnancy reported that thromboembolic complications occurred in 3.9% of women taking only warfarin, 9.2% of women who received unfractionated heparin in the first trimester followed by warfarin, and one fourth of women treated with unfractionated heparin throughout their pregnancy. Maternal death was observed in these groups in 2%, 4%, and 15%, respectively, and was usually related to prosthetic valve thrombosis (PVT).
surgery is not immediately available or when PVT is right-sided. However, cardiac surgery in pregnancy is associated with very high maternal and fetal mortality (6% and 30%, respectively) and morbidity (24% and 9%, respectively). 6 These patients are rarely considered for TT because of the concerns about bleeding and fetal harm and apprehension that thrombolytic agents are absolutely contraindicated in pregnancy. Recently, transesophageal echocardiography (TEE)-guided low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator (tPA) was demonstrated to be a safe and effective strategy for the treatment of PVT in a large, prospective study. 7 This trial involved 182 patients with 220 episodes of PVT. Low-dose, slow infusion of tPA protocol was associated with the highest (86%) thrombolytic success and lowest (10.5%) complication rates with no mortality, suggesting that guidelines for the treatment of PVT might need to be updated to reflect the utility of thrombolysis for all patients. In this study, we evaluated the safety and efficacy of this particular therapy in pregnant women With PVT.
Methods

Rationale of the Study Methods
Surgery Versus Thrombolytic Therapy
This study is the subgroup of Comparison of Different Transesophageal Echocardiography Guided Thrombolytic Regimens for Prosthetic Valve Thrombosis (TROIA) trial that was published earlier. 7 The study is nonrandomized because of the relatively small number of patients with this highly specific clinical condition, the very high morbidity and mortality associated with surgery from the available data, and the lack of evidence supporting superiority of either therapy. Furthermore, TT and surgery were not considered alternative treatment options; instead, they were considered complementary from the beginning of the study. Hence, TT was the first treatment option for virtually all pregnant patients with PVT, and surgery was considered only in patients who had an absolute contraindication to TT, failed thrombolysis, or refused to receive TT. The same thrombolytic protocol used in TROIA (25-mg tPA infusion in 6 hours in each thrombolytic session) was used in this study. We conducted a prospective audit of pregnant women with PVT treated with TT at any stage during pregnancy.
Why Low-Dose, Slow-Infusion tPA?
tPA is a highly fibrin-specific drug and does not cause systemic thrombolytic effect. The placental passage of tPA is minimal and not sufficient to cause unwanted fibrinolytic effect in the fetus. 8 It has short biological half-life and does not induce an antigenic reaction. We hypothesized that tPA could be an ideal agent for pregnant patients with PVT compared with streptokinase and urokinase. We also hypothesized that low-dose, slow infusion of tPA would lyse the clot gradually with reduced risk of thromboembolism and without compromising the success rates. Furthermore, we thought that bleeding risk could be reduced because tPA infusion would be stopped immediately with a slow infusion protocol.
TT Protocol and Dosing Regimen
Six-hour infusion of 25 mg tPA without a bolus (repeated once after 24 hours, up to 6 times if needed, for a maximum total dose of 150 mg) was used in all pregnant patients with PVT. We did not use intravenous heparin during tPA infusions to minimize bleeding risk. Heparin 70-IU/ kg bolus and 16 IU/kg per hour (up to 1000 IU/h) infusion with a target activated partial thromboplastin time of 1.5 to 2.0 times the mean of the reference range was started immediately after the tPA infusion. If repeat thrombolytic infusion was needed, heparin was held again until activated partial thromboplastin time was <50 seconds, and then tPA infusion was started. If the TT was successful, we started anticoagulation with heparin and warfarin. Warfarin was used when its daily dose was ≤2.5 mg during the first trimester after obtaining informed consent from the patient. Otherwise, enoxaparin was used to achieve peak anti-factor Xa activity of 0.7 to 1.2 IU/mL. Study patients with rethrombosis and patients with multiple mechanical valves were started on aspirin 300 mg daily in addition to anticoagulation. Patients received warfarin in the second and third trimesters up to the end of 35th week of pregnancy (international normalized ratio=2.5-4). They were hospitalized after that, and intravenous heparin was started until cesarean section. All pregnant patients underwent transthoracic echocardiographic and TEE immediately if they had any signs or symptoms suggesting PVT and every 12 weeks after the TT until delivery.
Inclusion and Exclusion Criteria
All pregnant patients with obstructive PVT, nonobstructive PVT with recent systemic thromboembolism and thrombus diameter of >5 mm, and asymptomatic mobile nonobstructive PVT with a thrombus diameter of at least 10 mm were included in this study. Patients with an absolute contraindication to TT, asymptomatic nonobstructive PVT patients without a history of recent thromboembolism and with thrombus diameter <10 mm, 7 and patients with imminent abortion or placenta previa were excluded. Patients with prosthetic valve obstruction who had no thrombus/mass/pannus in the TEE study and normal prosthetic valve leaflet motion were considered a patient-prosthesis mismatch and were excluded from the study.
Twenty-four consecutive pregnant patients with 28 episodes of PVT between December 2004 to March 2012 were included in this study. A PVT episode refers the entire treatment period of a patient who is admitted to the hospital with a PVT and includes all tPA infusions per thrombolytic regimen regardless of whether each infusion is successful. If the same patient was readmitted at a different time with rethrombosis of the prosthetic heart valve during pregnancy, the readmission was considered a separate PVT episode.
Clinical characteristics, including New York Heart Association functional class, demographics, and medications, were recorded into a database. All pregnant patients with mechanical heart valves routinely underwent 2-dimensional TEE (GE Medical Systems, Milwaukee, WI) between 2004 and 2008 and Philips IE33 2-dimensional TEE and real-time 3-dimensional TEE (Philips Medical Systems, Andover, MA) between 2008 and 2012 when they presented with thromboembolism or worsening New York Heart Association functional class or if transthoracic echocardiographic demonstrated prosthetic valve dysfunction, thrombus, or any echodensity suspicious for thrombus. Thrombus was recognized as a homogeneous, mobile, or fixed mass with as echodensity similar to the myocardium located at the valve occluder or valve struts and was visualized in all patients with PVT by echocardiography. All patients also underwent transthoracic echocardiographic and TEE examination within an hour after the thrombolytic sessions. Fetal assessment was performed by an obstetrician after admission and after every TT episode. Finally, fetal ultrasounds were obtained after TT and every 4 weeks until delivery. Fetal outcome was classified as termination of pregnancy before 20 weeks' gestation, miscarriage (spontaneous fetal loss at <20 weeks' gestation), stillbirth (fetal death at >20 weeks' gestation), baby death (neonatal or infant death), or live birth. Preterm birth was delivery before 37 weeks' gestation and included both spontaneous and iatrogenic preterm births.
All the risks, benefits, and alternatives of TT were explained to the patients in detail. Each patient gave written informed consent, and the study was approved by the local ethics committee.
Criteria for Thrombolytic Success
In patients with obstructive PVT, in the absence of fatal or nonfatal major complications, Doppler documentation of the resolution of increased gradient and decreased valve area, a reduction by ≥75% in major diameter or area of the thrombus, and clinical improvement in symptoms were considered the major criteria for TT success. Complete success was defined as all 3 criteria being met, and partial success was defined as <3 criteria being met. In patients with nonobstructive PVT, in the absence of fatal or nonfatal major complications, complete success was defined as ≥75% reduction in thrombus area or length. Partial success was defined as 50% to 75% reduction in thrombus area or length. For the interpretation of results in patients with PVT, partial and complete success rates were combined.
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Definition of Complications
Major fatal complication was defined as all-cause in-hospital mortality. Nonfatal major complications included ischemic stroke; intracranial hemorrhage; systemic thromboembolism; bleeding, including placental hemorrhage requiring transfusion or surgery; and tPA-related preterm delivery. Nonfatal minor complications were defined as bleeding without the need for transfusion and transient ischemic attack.
Statistical Analysis
Statistical analysis was performed with SPSS 19.0. All analyses were based on episodes. The variables were investigated with the use of analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk test) to determine whether they are approximately normally distributed. Descriptive statistics were reported as mean, standard deviation, median, and minimum and maximum values for continuous variables and as frequencies with percentages for the categorical variables. The paired t test was used to compare pre-TT and post-TT prosthetic valve area and peak and mean gradients. The significance level was set at P=0.05.
Results
Over an 8-year period, 24 women received tPA during 25 pregnancies with 28 episodes of PVT. Their mean age was 29±6 years (range, 19-42 years). The demographic and clinical characteristics are reported in Table 1 . The mean gestational age on admission was 19±11 weeks (range, 6-36 weeks). The most common symptom was dyspnea (n=18, 64%). Three patients were asymptomatic. Only 1 episode presented with transient ischemic attack. Patients had atrial fibrillation in 14% of PVT episodes (n=4). Two patients (7%) were using low-dose aspirin (100 mg) on admission. None of the patients had hypertension or diabetes mellitus. There was no medication use other than warfarin, aspirin, and prenatal vitamins. Twenty-three women had only mechanical mitral valves, and 1 patient had a mechanical mitral and a normally functioning aortic valve. All PVT episodes involved mitral prosthesis only. Poor compliance with warfarin or subtherapeutic anti-factor Xa or international normalized ratio level was detected in 26 of 28 episodes (93%) on admission. Fifteen episodes occurred on warfarin therapy (international normalized ratio levels on admission were <2 in all except 1 of them), and 10 episodes occurred in patients who were on enoxaparin. Three patients had rethrombosis during the same pregnancy; 1 woman had PVT in her second pregnancy. Fourteen episodes (50%) occurred in during the first trimester, 4 (14%) in the second trimester, and 10 (36%) in the third trimester. Three patients declined TT and wished to proceed with surgery. One of these patients (28 weeks' pregnant) and the fetus died during surgery.
Echocardiographic Results
In obstructive PVT episodes (n=15, 54%), the mean valve area was 1.2±0. ; P=0.022). There was no remaining thrombus after TT on TEE. Figure 1 demonstrates Doppler tracing ( Figure 1A ), 2-dimensional TEE ( Figure 1B) , and 3-dimensional TEE ( Figure 1C ) images (see also Movies I and II in the online-only Data Supplement) of one of the study patients with obstructive thrombus.
Maternal and Fetal Outcomes
There were 20 live births, including 1 delivery that occurred on the 30th week of pregnancy in a 42-year-old woman as 
TT Outcomes
The average dose of TT per PVT episode used was 48.7±29.5 mg (median, 27.5 mg; range, 25-100 mg). All episodes resulted in complete thrombolytic success. The initial rate of success after the first dose of tPA thrombosis was 47% (7 of 15) in the obstructive PVT group and 61% (8 of 13) in the nonobstructive PVT group. The average dose to obtain complete thrombus lysis was similar between the obstructive and nonobstructive PVT groups (54.3±30.8 mg in the obstructive PVT group versus 42.3±27.7 mg in the nonobstructive PVT group; P=0.23; Figure 2 ).
Discussion
This single-center, prospective study including a relatively large number of pregnant patients with PVT demonstrated that low-dose, slow infusion of tPA was associated with successful thrombus lysis in all episodes. Our findings also indicated that the incidence of maternal and fetal adverse events with this protocol was lower than with surgery or medical therapy on the basis of the available published data. Therefore, low-dose, slow infusion of tPA with repeated doses as needed under TEE guidance seems to be effective and relatively safe for both mother and fetus, and we suggest that it should be used as first-line therapy for PVTs in pregnant women. Currently, there are no evidence-based guidelines for pregnancies complicated by PVT. We performed a comprehensive literature review on articles discussing TT in pregnant patients with PVT (Table 2 ) and compared the TT outcome results of our study with the published articles ( Table 3) . Overall, TT has been administered in 32 pregnancies (38 episodes) complicated by PVT. These reports yielded average thrombolytic success, maternal mortality, major complication, and minor complication rates of 76%, 10%, 14%, and 32%, respectively. Fetal/neonatal mortality was 28%. Similarly, Leonhardt et al 35 reported a literature review on TT with tPA (reteplase or alteplase) used in 21 pregnant patients for the treatment of non-PVT causes such as stroke (n=10), pulmonary embolism (n=7), deep venous thrombosis (n=3), and myocardial infarction (n=1). The report did not include case reports after delivery and use of other thrombolytic drugs. Thrombolytic success, maternal mortality, and morbidity were 71%, 5%, and 24%, respectively. Fetal/neonatal mortality was 24%. In our study, the TEE-guided, low-dose, slow-infusion tPA protocol was associated with 100% thrombolytic success with no maternal mortality. Fetal mortality was 20%. In general, TT for the treatment of PVT in nonpregnant patients is successful in ≈85% of patients. [36] [37] [38] [39] [40] [41] [42] [43] On the other hand, our protocol demonstrated a complete success rate among all pregnant patients with PVT. This could be explained by the fresh and rapid development of clot in this specific patient population compared with nonpregnant patients with gradually developed and organized thrombus. These findings suggest that low-dose, slow infusion of tPA can dramatically improve maternal or fetal outcomes in pregnant patients with PVT and that this effect may be more pronounced as a result of the nature of the thrombus in pregnant patients compared with nonpregnant patients.
Administration of TT is considered a relative contraindication during pregnancy. 4, 5 Therefore, clinicians hesitate to use TT during pregnancy because of the anticipated maternal and fetal risk of hemorrhagic and thromboembolic complications. The risks of TT during pregnancy have never been evaluated with randomized trials. The best level of evidence comes from case reports or case series. Although TT in these reports was performed with a different drug, a different protocol, and various indications, the overall complication rates of TT in these patients are not worse than the complication rates in the large randomized TT trials on stroke, myocardial infarction, and pulmonary embolism. [44] [45] [46] [47] PVT during pregnancy is uncommon but requires urgent therapy. Among 172 pregnancies with thrombotic disorders, there were only 4 cases of PVT, and the most commonly used regimen in these patients was streptokinase, which was initiated for mostly deep venous thrombosis or pulmonary embolism. Only 5 of these 172 pregnant women received tPA for the treatment of acute thrombosis. 47 There was no maternal death resulting from any TT in that report. However, surgery is traditionally considered a first-line therapy in patients with PVT. Cardiac surgery exposes mother and child to a greater risk than TT does. 6 It is associated with very high maternal and fetal mortality (6% and 30%, respectively) and morbidity (24% and 9%, respectively), suggesting that the risk might exceed the risk of administration of TT.
A specific concern with TT in pregnancy is increased risk of spontaneous abortion. The incidence of this complication with different anticoagulant regimens is up to 37.5% in patients with a prosthetic heart valve. 2, 3 McLintock et al 3 reported a spontaneous abortion rate of 26% with only oral anticoagulation, 23% with heparin in the first trimester followed by oral anticoagulation, and 9% with lowmolecular-weight heparin in the first trimester followed by oral anticoagulation during pregnancy. Approximately one quarter of pregnant patients on oral or intravenous anticoagulation develop miscarriage. The incidence of spontaneous miscarriage in Turkish pregnant women who were not on oral anticoagulants was reported as 20%. 48 In our study, spontaneous miscarriages occurred in 5 episodes (20%). Although the total number of miscarriages was too low to make a definite conclusion, it was similar to the expected rate among this specific patient population, suggesting that our protocol did not increase the baseline miscarriage rate. This observation seemed robust, especially in patients who received fewer TT sessions and small doses of oral anticoagulation. One woman who was on warfarin 7.5 mg/d developed placental hemorrhage after TT. She had received 3 sessions of heparin after 3 doses of tPA, which could have caused the development of placental hemorrhage. Her baby had total hearing loss, which could also be secondary to the high-dose warfarin rather than the tPA. Nevertheless, our findings indicate that this TT protocol is associated with a successful thrombus lysis in pregnant PVT patients without increasing the complication rates for mother and fetus.
Study Limitations
Our study is a single-center, nonrandomized, observational study. However, it has remarkable size for this specific study population. All pregnant patients with PVT were treated similarly in our hospital. All patients had thrombosed mitral mechanical valves. Therefore, the applicability of our findings to other mechanical and bioprosthetic valves may be questionable. Finally, this study is not a head-to-head comparison of TT and surgery for the treatment of PVT in pregnant patients. However, among 3 patients who underwent surgery in our patient population, 1 patient (and fetus) died, which may reflect the high mortality of this strategy.
Conclusions
Low-dose, slow infusion of tPA with repeat doses as needed is an effective therapy with very high thrombolytic success rate for the treatment of PVT in pregnant women. This protocol also seems to be safer than cardiac surgery or alternative medical strategies published to date. TT should be considered first-line therapy in pregnant patients with PVT. 
